moderna flu - Search News

Moderna says FDA to review its flu vaccine

Digest more

· 12h · on MSN

Moderna says FDA to review its flu vaccine after reversing course

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

· 2h

Moderna says the FDA will consider its new flu shot after resolving a public dispute

· 13h

FDA to review Moderna's mRNA flu vaccine after initial rejection

· 16h

FDA reverses course and will review Moderna’s mRNA flu shot, company says

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday.

· 16h

FDA reverses course, will review Moderna's mRNA flu vaccine

· 16h

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

11hon MSN

US FDA reverses course, will review Moderna's flu vaccine application

By Mariam Sunny and Michael Erman Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug Administration changed course and will review its new flu vaccine, a week after rejecting the original submission and fueling drugmaker and investor concerns over policy changes at the agency under the administration of President Donald Trump.

18h

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

The study involved 550 healthy U.S. adults ages 18 to 75 who received either the experimental combo vaccine and a placebo or two separate shots of Moderna’s commercially available mRNA flu and COVID vaccines, according to a report published in Human Vaccines and Therapeutics.